Empiric antibiotic therapy for Staphylococcus aureus bacteremia may not reduce in-hospital mortality: a retrospective cohort study.

PloS One
Marin L SchweizerEli N Perencevich

Abstract

Appropriate empiric therapy, antibiotic therapy with in vitro activity to the infecting organism given prior to confirmed culture results, may improve Staphylococcus aureus outcomes. We aimed to measure the clinical impact of appropriate empiric antibiotic therapy on mortality, while statistically adjusting for comorbidities, severity of illness and presence of virulence factors in the infecting strain. We conducted a retrospective cohort study of adult patients admitted to a tertiary-care facility from January 1, 2003 to June 30, 2007, who had S. aureus bacteremia. Time to appropriate therapy was measured from blood culture collection to the receipt of antibiotics with in vitro activity to the infecting organism. Cox proportional hazard models were used to measure the association between receipt of appropriate empiric therapy and in-hospital mortality, statistically adjusting for patient and pathogen characteristics. Among 814 admissions, 537 (66%) received appropriate empiric therapy. Those who received appropriate empiric therapy had a higher hazard of 30-day in-hospital mortality (Hazard Ratio (HR): 1.52; 95% confidence interval (CI): 0.99, 2.34). A longer time to appropriate therapy was protective against mortality (HR: 0....Continue Reading

References

Dec 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J Romero-VivasJ J Picazo
Dec 10, 1998·Journal of Internal Medicine·L LeiboviciS D Pitlik
Jun 4, 1999·American Journal of Epidemiology·M SalasB H Stricker
Oct 19, 1999·Journal of Clinical Microbiology·B ShopsinB N Kreiswirth
Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G LinaJ Etienne
Feb 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A SorianoE Soriano
Nov 14, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J M Mylotte, A Tayara
Jun 23, 2001·The Journal of Antimicrobial Chemotherapy·J M Andrews
Dec 20, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E CosgroveYehuda Carmeli
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P LodiseMichael J Rybak
Jan 1, 2004·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Olivier LesensDaniel Christmann
Dec 14, 2004·American Journal of Respiratory and Critical Care Medicine·Peter W KimMary-Claire Roghmann
Mar 11, 2005·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Sara E CosgroveYehuda Carmeli
Dec 2, 2005·Emerging Infectious Diseases·Jon P FurunoAnthony D Harris
Feb 8, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S-H KimK-W Choe
Mar 1, 2006·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R KhatibL B Johnson
Apr 26, 2006·The Journal of Antimicrobial Chemotherapy·Graeme N ForrestRichard A Venezia
Nov 14, 2006·Journal of Clinical Epidemiology·Jessina C McGregorAnthony D Harris
Dec 19, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin E StryjewskiVance G Fowler
Dec 30, 2006·Antimicrobial Agents and Chemotherapy·Regina B OsihAnthony D Harris
Feb 24, 2007·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J GómezM Valdés
Mar 21, 2007·Emerging Infectious Diseases·Rebecca H SunenshineArjun Srinivasan
May 24, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Jon P FurunoEli N Perencevich
Jun 30, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jessina C McGregorJon P Furuno
Oct 24, 2007·Emerging Infectious Diseases·Jennifer K JohnsonMary-Claire Roghmann
Oct 14, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J O RobinsonR J Murray
Sep 2, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Heidi AmmerlaanUNKNOWN European Practices of Infections with Staphylococcus aureus (SEPIA) Study Group

❮ Previous
Next ❯

Citations

Sep 28, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Karri A BauerDebra A Goff
Dec 22, 2010·Antimicrobial Agents and Chemotherapy·Marin L SchweizerEli N Perencevich
Jun 20, 2012·Emerging Infectious Diseases·Mina PastagiaStephen G Jenkins
Oct 16, 2010·The Journal of Antimicrobial Chemotherapy·Mical PaulLeonard Leibovici
May 18, 2011·Hospital Practice·Peggy S McKinnonAlpesh N Amin
Jan 20, 2016·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Andrew E SimorUNKNOWN Canadian Nosocomial Infection Surveillance Program
Jun 15, 2011·The Journal of Hospital Infection·H R DayD J Morgan
Mar 16, 2011·The Journal of Infection·Hilmir AsgeirssonOlafur Gudlaugsson
May 9, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Carley B EmersonJon P Furuno
Feb 8, 2013·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Hannah R DayDaniel J Morgan
Apr 19, 2015·Critical Care : the Official Journal of the Critical Care Forum·Kristel MarquetNeree Claes
May 29, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J LeG Sakoulas
Feb 9, 2017·BMC Infectious Diseases·Kim O GradelUNKNOWN Danish Collaborative Bacteraemia Network (DACOBAN)
Apr 12, 2012·Clinical Microbiology Reviews·Sebastian J van HalIain B Gosbell
Aug 25, 2010·Antimicrobial Agents and Chemotherapy·Mical PaulLeonard Leibovici
Dec 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sjoukje H S WoudtUNKNOWN Infectious Diseases Surveillance Information System–Antimicrobial Resistance (ISIS-AR) Study Group

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.